Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 10/20 | 0.51 |
| ▸ | PPARA | Q07869 | 9/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220160 | 0.89 | PPARD (0.66) | PPARDNPC1RAB9APPARGPPARA | |
| SCHEMBL10219884 | 0.87 | PPARD (0.65) | PPARDNPC1RAB9APPARGPPARA | |
| SCHEMBL10219857 | 0.85 | PPARG (0.55) | PPARDNPC1RAB9APPARGPPARA | |
| SCHEMBL10219886 | 0.84 | PPARD (0.61) | PPARDNPC1RAB9APPARGPPARA | |
| SCHEMBL10219880 | 0.84 | PPARD (0.59) | PPARDNPC1RAB9APPARGPPARA | |
| SCHEMBL10219891 | 0.79 | PPARD (0.64) | PPARDNPC1RAB9APPARGPPARA | |
| SCHEMBL10219910 | 0.79 | PPARD (0.79) | PPARDNPC1RAB9APPARGPPARA | |
| SCHEMBL10219912 | 0.79 | PPARD (0.69) | PPARDPPARGPPARA | |
| SCHEMBL10220794 | 0.78 | PPARD (1.00) | PPARDPPARGPPARA | |
| SCHEMBL14144180 | 0.77 | PPARD (0.62) | PPARDNPC1RAB9APPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885NPC1 1742/4885RAB9A 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.